AstraZeneca Readies New Portfolio of Targeted Cancer Therapies

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.



Source link

About The Author

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top